December 2, 2024- Medtronic plc announced new data for the Evolut™ Transcatheter Aortic Valve Replacement System (TAVR) at PCR London Valves 2024. This new clinical evidence brings further insights to global implanters treating patients with symptomatic severe aortic stenosis (SASS). New findings from the Optimize PRO clinical study demonstrated favorable procedural and clinical outcomes following use of an optimized care pathway and the cusp overlap technique (COT) to deploy Evolut™ valves. Additionally, a pooled analysis of Evolut™ PRO patients was shared showing improvement in rates of paravalvular leak (PVL) in TAVR patients, over time following hospital discharge.